Novo Nordisk

Sun Pharma receives regulatory approval to sell generic Wegovy in India

Sun Pharma said it will launch generic semaglutide in India after the patent expiry in March 2026, becoming the second domestic drugmaker to secure regulatory approval for the blockbuster drug

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.

US FDA asks drugmakers to drop suicide warnings on weight-loss drugs

The FDA had reached similar conclusion following a preliminary review in 2024, but had acknowledged at the time that it could not rule out a small risk because of limited data

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

Semaglutide patent loss to create ₹5,000 crore opportunity: Report

Patent expiries of blockbuster weight-loss drug semaglutide may create a ₹5,000 crore generic opportunity for Indian pharma firms across India and key emerging and regulated markets

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Novo Nordisk secures US FDA approval for first weight-loss pill

US-listed shares of Novo jumped 8 per cent and Lilly fell 1 per cent in extended trading after the approval announcement

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

With an eye on rivals, Novo Nordisk launches diabetes drug Ozempic in India

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

Novo Nordisk challenges HC order permitting Dr Reddy's semaglutide exports

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Delhi HC refuses to halt order allowing Dr Reddy's to export Semaglutide

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision

Delhi HC allows Sun Pharma to export semaglutide, restricts sale in India

The Delhi High Court has allowed Sun Pharma to manufacture and export semaglutide-based drugs to countries where Novo Nordisk holds no patent, but barred sales in India until March 2026

Delhi HC allows Sun Pharma to manufacture, export its weight loss drug

The approval marks a major win for Sun Pharma in its patent dispute with Danish drugmaker Novo Nordisk, the company that manufactures weight loss drug Ozempic

Novo Nordisk moves HC to stop Sun Pharma's weight-loss drug launch

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Price cuts drove market gains in November for Novo Nordisk's Wegovy

Novo Nordisk cut Wegovy prices in mid-November, driving a 70% consumption jump and higher market share. Pharmarack data show Lilly's Mounjaro still dominates sales

Healthify seeks more weight-loss drug partnerships after Novo Nordisk deal

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base

Novo sticks to oral semaglutide amid rising demand for injectables

Novo Nordisk will strengthen its oral semaglutide portfolio led by Rybelsus while cutting Wegovy injection prices by up to 37% to improve accessibility and expand its market in India

Novo Nordisk cuts weight-loss drug Wegovy prices by up to 37% in India

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

Novo Nordisk, Emcure Pharmaceuticals tie up to expand Wegovy's girth

2.4 mg injectable Poviztra to mark next phase of weight-loss rollout

Novo Nordisk, Emcure Pharma to launch weight-loss drug under new brand

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk's reach is limited